Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

EQT Life Sciences Exits Tubulis Investment Following Gilead Acquisition Agreement in Oncology Sector

Summary by EuropaWire.eu
Open the article to view the coverage from EuropaWire.eu
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

bionity.combionity.com

Evotec Expects to Receive Approximately $100 Million From the Acquisition of Tubulis.

Evotec SE announced that it expects to receive approximately $100 million in upfront proceeds from Gilead Sciences' acquisition of Tubulis GmbH upon closing of the transaction. In addition, Evotec is entitled to further contingent payments of up to approximately $58 million...

Read Full Article
EuropaWire.euEuropaWire.eu

EQT Life Sciences Exits Tubulis Investment Following Gilead Acquisition Agreement in Oncology Sector

Open the article to view the coverage from EuropaWire.eu

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

EuropaWire.eu broke the news on Wednesday, April 8, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Gilead Sciences icon

Gilead Sciences

Germany icon

Germany

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal